Novartis | NVS - Cost Of Sales


Novartis reported $3.46B in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Amgen USD 1.87B 271M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Bausch Health Companies USD 997M 18M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Canopy Growth CAD 62.98M 9.91M Mar/2026
Corcept Therapeutics USD 4.06M 1.18M Jun/2026
Drreddys Laboratories INR 32.13B 8.34B Mar/2026
Eli Lilly USD 3.27B 309M Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
J&J USD 8B 67M Jun/2026
Merck USD 3.14B 200M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Novartis USD 3.46B 83M Mar/2026
Pacira USD 58.49M 7.75M Jun/2026
Perrigo USD 708.9M 65.2M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Phibro Animal Health USD 240.42M 2.58M Dec/2025
Prestige Brands USD 135.22M 5.54M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
Sanofi EUR 3.14B 618M Mar/2026
Supernus Pharmaceuticals USD 59M 9.97M Jun/2026
Zoetis USD 704M 32M Jun/2026